**Odyssey Group International Secures Concussion Treatment Asset: Prevacus Drug Candidate Poised for Human Trials**

The concussion treatment landscape is undergoing a significant shift following a major asset acquisition announcement. Odyssey Group International, Inc. (OTCQB: ODYY), a technology and asset acquisition company specializing in life-saving medical innovations, has entered into a definitive agreement to acquire the drug candidate PRV-002 from biopharmaceutical firm Prevacus, Inc. This all-stock transaction marks a strategic move to accelerate development of what could become the first therapeutic treatment specifically designed for concussion and mild traumatic brain injury (mTBI).

**The Market Opportunity Behind the Deal**

The scale of the opportunity underscores why this acquisition matters. In the United States alone, more than 3 million sports and recreational concussions occur annually, with an estimated 1.5 million additional cases going unreported. Beyond sports injuries, concussions also stem from motor vehicle accidents and elderly falls, dramatically expanding the addressable patient population. Industry analysts estimate the annual market for an effective concussion treatment at over $2 billion, reflecting both the prevalence of the condition and the absence of FDA-approved therapeutic options currently available.

**Prevacus Innovation: A Novel Approach to Brain Injury**

What distinguishes Prevacus's approach is its molecular-level strategy. PRV-002 utilizes gene amplification technology to simultaneously target multiple pathological mechanisms—reducing swelling, inflammation, and oxidative stress in the injured brain. The compound is delivered via nasal administration using a nanoparticle drug formulation, a method that enhances bioavailability to the brain. Preclinical animal studies have demonstrated both safety and efficacy, with toxicology data revealing a significant safety margin. Brain biodistribution studies further showed the drug reaches target areas in less than 5 minutes, a critical advantage for acute injury treatment.

**Notable Support and Development Timeline**

Prevacus has garnered backing from prominent figures in professional sports, including Brett Favre, who has served as both an investor and scientific advocate. The Phase 1 clinical trial site, protocol, and clinical research organization (CRO) are already established, positioning the program for rapid advancement into human studies. The acquisition is expected to close by the end of February 2021, subject to Prevacus shareholder approval and customary closing conditions.

**Strategic Rationale and Future Direction**

Dr. Jake Vanlandingham, Chief Executive Officer of Prevacus, will join Odyssey to lead continued PRV-002 development. In his statement, he emphasized how Odyssey's management expertise and funding capabilities will accelerate the program: "The Odyssey team provides the resources and mechanism to enhance our nanoparticle delivery system and propel PRV-002 toward clinical validation. Human Phase 1 trials are planned for this year."

Michael Redmond, Chairman and CEO of Odyssey Group International, highlighted the company's confidence in the asset: "Our partnership with Prevacus over the past two years allowed us to observe PRV-002's promising trajectory. Acquiring this asset directly benefits Odyssey shareholders while enabling us to bring a potential breakthrough treatment closer to patients who need it."

**Why This Matters for the Concussion Space**

Concussion has emerged as a significant public health concern affecting athletes, military personnel, and aging populations. The heterogenous nature of traumatic brain injury demands treatments that address multiple biological pathways simultaneously—something conventional single-mechanism therapeutics cannot achieve. If successful in human trials, PRV-002 could represent a meaningful advancement in how the medical community treats acute brain injury.

The transaction reflects broader investor confidence in the biopharmaceutical space and a recognition that unmet medical needs can attract substantial capital when coupled with novel science. For Odyssey shareholders and the broader medical community, this acquisition represents an opportunity to monitor the clinical validation of a unique therapeutic approach to one of medicine's persistent challenges.